Cytokinetics Announces Data From Phase 1 Study of CK-4021586
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/23/2026
- Wall Street ends down as oil prices, Treasury yields rise
- BTIG’s Krinsky warns 2000-like signals are mounting
- HSBC remains max bullish on stocks, tells investors to lean into tech
- Analyst explains why the midterm outcome is a “fundamental non-event”
- Oil settles up around 4% as Iran's president vows to never surrender
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- On Holding sets 2029 financial targets, authorizes $1B share buyback
- Nasdaq reaches record high close, AI stocks rally
- Elmet Group signs tungsten offtake deal with Hemerdon Mine
- Meta bull case increasingly playing out, Mizuho says
Goldman Sachs Reiterates Neutral Rating on Cytokinetics (CYTK)
September 9, 2024 12:11 PM EDTGoldman Sachs analyst Paul Choi reiterated a Neutral rating and $60.00 price target on Cytokinetics (NASDAQ: CYTK).
The analyst comments "Overall consistent results support advancing CK-586 into Phase 2 studies though greater conviction remains elusive for now. We reviewed the results of a Phase 1... More
